BMX-001 is named as an intervention in 2 current clinical trials in our USA and Mexico registers. 1 is recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is BioMimetix JV, LLC (1). The most-studied condition is Ovarian Neoplasms.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
NCT06532279 · ClinicalTrials.gov ↗ · Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
|
Phase 2 | Recruiting | NRG Oncology | Mexico |
|
BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer
NCT06620029 · ClinicalTrials.gov ↗ · Ovarian Neoplasms, Endometrial Cancer, Endometrial Neoplasm
|
Phase 1/2 | Not yet open | BioMimetix JV, LLC | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| BioMimetix JV, LLC | 1 |
| NRG Oncology | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 1 | 0 |
| Clinical trials in Mexico | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our USA and Mexico registers name BMX-001 (also registered as MnSOD Mimetic BMX-001) as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in Mexico. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
BioMimetix JV, LLC (1) and NRG Oncology (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how BMX-001 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how BMX-001 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists BMX-001 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.